Quote:
VANCOUVER, Washington, May 24, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Cyrus Arman, the Company’s President, has taken a medical leave of absence. During Dr. Arman’s absence, Antonio Migliarese, the Company’s Chief Financial Officer, will assume interim President responsibilities. Mr. Migliarese will be supported by the Company’s recently appointed interim Chief Medical Officer, Dr. Melissa Palmer, as well as Dr. Salah Kivlighn, who recently joined the Company as a clinical and strategic advisor, in collectively leading the Company’s continued priorities of lifting the clinical hold on the use of leronlimab in the HIV population, advancing the development of the NASH phase 2b clinical trial for submission to the FDA, and exploring potential strategic business opportunities. The Company plans to host an investment community webcast on a to-be-announced date in the near future.
Cyrus will heal. But, he can heal at his leisure. He doesn't need to quickly return to sign the NDAs into effectiveness once the hold lifts. Why is that? Because Antonio Migliarese is at the helm and he may sign these agreements and make them active so that when Cyrus returns, he returns as CEO.
Soon after the hold lifts, the conference call is scheduled and the potential collaborations may be discussed at that time.
(4)
(0)